Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Reverse Stock Split
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company’s Complete HDE Submission
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
From InVivo Therapeutics Holdings Corp.
Via Business Wire
Tickers NVIV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.